Halozyme Receives Milestone Payment of $10M from Roche Following Commercial Launch of Herceptin SC

Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that the commercial launch of Herceptin® SC in Europe has triggered a $10 million milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. This time-saving subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's recombinant human hyaluronidase (rHuPH20)